Craft

Nektar Therapeutics

Stock Price

$0.6

2023-05-26

Market Capitalization

$119.6 M

2023-05-26

Revenue

$92.1 M

FY, 2022

Nektar Therapeutics Summary

Company summary

Overview
Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.
Type
Public
Status
Active
Founded
1990
HQ
San Francisco, CA, US | view all locations
Website
http://www.nektar.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Jeff Ajer, Director

    • Robert B. Chess, Chairman of the Board

      • Gil M. Labrucherie, Chief Operating Officer and Chief Financial Officer

        • R. Scott Greer, Director

          LocationsView all

          3 locations detected

          • San Francisco, CA HQ

            United States

            455 Mission Bay Boulevard South, San Francisco

          • Huntsville, AL

            United States

            1112 Church St NW

          • Hyderabad, TG

            India

            Main Rd, Hashmath Gunj, Goutam Nagar, Badi Chowdi, Kachiguda

          Nektar Therapeutics Financials

          Summary financials

          Revenue (Q1, 2023)
          $21.6M
          Gross profit (Q1, 2023)
          $14.5M
          Net income (Q1, 2023)
          ($137.0M)
          Cash (Q1, 2023)
          $77.0M
          EBIT (Q1, 2023)
          ($134.7M)
          Enterprise value
          $170.8M

          Footer menu